Overcoming Immunological Barriers for Preclinical Studies of Cardiac Stem Cell
Abstract
Many veterans suffer from ischemic cardiomyopathy partly resulting from exposure to Agent Orange. Due to thelimited supply of donor hearts and potential complications from chronic immunosuppressive therapy, investigatorshave turned to therapeutic approaches aimed at improving myocardial function, namely, cell transplantation. Thepurpose of this proposal is to generate non-immunogenic human embryonic stem cell-derived left ventricularcardiomyocytes as a potential off-the- shelf candidate for cardiac cell transplantation. Success of this proposalwould address the increasing health burden of veterans suffering from ischemic cardiomyopathy. A nonimmunogenic universal donor cell line (Elf1) was previously developed to bypass host immune recognition andresponse. We have made progress in expanding and characterizing the pluripotency of this cell line. We confirmedthat these cells express high levels of pluripotency markers indicative of their stem cell state. We are currentlytransitioning them from a feeder to feeder-free system as well as switching fromNave to Primed state that is required for our cardiac differentiation.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2021
- Accession Number
- AD1145302
Entities
People
- Arash Pezhouman
Organizations
- University of California